Gerardo Bueso, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1578658001
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 1,239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations.
Across 1,239 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$2K
- Amgen$2K
- Mannkind Corporation$1K
- Lilly USA, LLC$983
- Boehringer Ingelheim$968
- plus $12K from 54 others
Across 131 payments — averaging $8793.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$480K
- AstraZeneca$418K
- Kowa Research Institute, Inc.$133K
- Sanofi US Services Inc.$73K
- Boehringer Ingelheim$23K
- Astrazeneca UK Limited$9K
- plus $15K from 6 others
What the payments were for
- Speaking & faculty fees$1251%
- Travel & lodging$2251%
- Food & beverage$20,69197%
- Education$1451%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALLANT$651
- QUADRA ASSURA$351
- Diamondback Peripheral$167
- NATPARA (PARATHYROID HORMONE)$125
- XARELTO$110
How this compares
$21,304 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 888 | $1,615,738 |
| FarxigaDapagliflozin Propanediol | 233 | $281,198 |
| TrulicityDulaglutide | 164 | $249,970 |
| MounjaroTirzepatide | 139 | $233,307 |
| JardianceEmpagliflozin | 170 | $229,256 |
| JanumetSitagliptin Phos/Metformin Hcl | 143 | $185,530 |
| OmnitropeSomatropin | 16 | $128,909 |
| Tresiba Flextouch U-100Insulin Degludec | 159 | $75,253 |
| JanuviaSitagliptin Phosphate | 72 | $70,423 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $64,097 |
| ProliaDenosumab | 34 | $58,163 |
| EliquisApixaban | 45 | $51,123 |
| TradjentaLinagliptin | 33 | $48,505 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $46,765 |
| Repatha SureclickEvolocumab | 42 | $41,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $2,250 | $1,653,156932 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humatrope | $983 | $522,773390 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $968 | $335,965246 claims |
| AstraZenecaFarxiga | $819 | $281,198233 claims |
| MerckJanumet, Januvia | $248 | $255,953215 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,583 | $86,98145 claims |
| PfizerEliquis | $47 | $51,12345 claims |
| Johnson & JohnsonXarelto | $195 | $18,82718 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $14,99714 claims |
| NovartisEntresto | $367 | $13,68013 claims |
| AbbVieSynthroid | $687 | $12,330136 claims |
| Esperion Therapeutics, Inc.Nexlizet | $356 | $9,51815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Andres SplenserHouston$923K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Laila TabatabaiHouston$207K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.